Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Tax Provisions for 6 consecutive years, with $85.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 44.03% year-over-year to $85.7 million, compared with a TTM value of $226.8 million through Dec 2025, up 56.74%, and an annual FY2025 reading of $226.8 million, up 56.74% over the prior year.
  • Tax Provisions was $85.7 million for Q4 2025 at Neurocrine Biosciences, up from $82.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $85.7 million in Q4 2025 and bottomed at -$26.7 million in Q1 2023.
  • Average Tax Provisions over 4 years is $34.7 million, with a median of $33.6 million recorded in 2024.
  • Peak annual rise in Tax Provisions hit 322.22% in 2021, while the deepest fall reached 426.67% in 2021.
  • Year by year, Tax Provisions stood at $15.2 million in 2021, then skyrocketed by 321.71% to $64.1 million in 2023, then fell by 7.18% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025.
  • Business Quant data shows Tax Provisions for NBIX at $85.7 million in Q4 2025, $82.3 million in Q3 2025, and $52.0 million in Q2 2025.